Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
58 hedge funds and large institutions have $28.2M invested in Kronos Bio in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 7 closing their positions.
3% less funds holding
Funds holding: 60 → 58 (-2)
9.82% less ownership
Funds ownership: 45.93% → 36.11% (-9.8%)
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
16% less capital invested
Capital invested by funds: $33.5M → $28.2M (-$5.24M)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.12M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$283K |
| 3 |
Renaissance Technologies
New York
|
+$135K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$130K |
| 5 |
AI
Acuitas Investments
Seattle,
Washington
|
+$129K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$3.26M |
| 2 |
PA
Perceptive Advisors
New York
|
-$2.19M |
| 3 |
PCIG
Partners Capital Investment Group
Boston,
Massachusetts
|
-$1.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$413K |
| 5 |
D.E. Shaw & Co
New York
|
-$319K |
KRON Hedge Fund Activity: Q1 2024 in Review
58 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q1 2024, worth a combined $28.2M — down 16% from $33.5M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of KRON and 5 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was Millennium Management, adding an estimated $1.12M. The largest seller was Omega Fund Management, cutting an estimated $3.26M.
- 58 institutional investors held Kronos Bio (KRON) as of Q1 2024, down from 60 in Q4 2023.
- Funds reported $28.2M of Kronos Bio stock for Q1 2024, down 16% quarter-over-quarter.
- 5 funds opened new Kronos Bio positions in Q1 2024 and 7 closed out, a net change of -2 holders.
- The largest Kronos Bio buyer in Q1 2024 was Millennium Management, an estimated $1.12M added.
- The largest Kronos Bio seller in Q1 2024 was Omega Fund Management, an estimated $3.26M sold.
Based on aggregated 13F filings for Q1 2024.